ACOG Alpha Cognition Inc.

NEUTRAL Impact: 3/10 8-K
Horizon weeks Filed Apr 20, 2026 Processed 1mo ago SEC 0001213900-26-045668
8-K context-dependent: Items 5.02
Latest settled — T+20d
ACOG ▼ -16.42% at T+20d
NEUTRAL call ✗ call lost -16.42% · α vs SPY -21.34% · entry $6.88 → $5.75
Next anchor: T+60d in 5w
Last close $6.02 (close Jun 8) · -12.50% from $6.88 entry
Entry anchored
Apr 20, 02:57 PM ET
via Databento tick
T+1d
+1.60%
call +1.60% · α +0.58%
$6.99
settled 7w ago
T+5d
-9.88%
call -9.88% · α -10.97%
$6.20
settled 6w ago
T+20d
-16.42%
call -16.42% · α -21.34%
$5.75
settled 23d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

Alpha Cognition Inc. appointed Bethany Sensenig to its board of directors on April 15, 2026. Sensenig brings extensive biopharma CFO experience from Radius Health, 9 Meters Biopharma, and Biogen, and will receive an initial equity grant of 5,489 RSUs and 6,991 stock options, both vesting after one year.

Actionable Insight

Monitor upcoming proxy filings for full director compensation details and potential committee assignments. No immediate financial impact expected, but investor sentiment may improve given Sensenig's strong biopharma CFO background.

Key Facts

  • Bethany Sensenig appointed to board on April 15, 2026
  • Prior CFO roles at Radius Health, 9 Meters Biopharma, Minovia Therapeutics, and Biogen
  • Also serves on boards of Supernus Pharmaceuticals (SUPN) and KalVista Pharmaceuticals (KALV)
  • Received 5,489 restricted stock units and 6,991 stock options with $6.65 exercise price
  • All equity awards vest one year after grant date

Financial Impact

Approximately $83,000 in initial equity grants based on current stock price and grant size

share countequity compensation expense

Risk Factors

  • Minimal near-term risk; equity grant could lead to modest dilution upon vesting
  • No operational changes indicated with this appointment

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-045668
Document: 0001213900-26-045668-index-headers.html0001213900-26-045668
Document: 0001213900-26-045668-index.html0001213900-26-045668
Document: 0001213900-26-045668.txt0001213900-26-045668
3 reports for ACOG
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ACOG — sortable, filterable
Type Now
May 19, 2026
21d ago
Insider Cluster
BULLISH ★ 5/10
$5.89 $5.94▲ +0.85%▼ −0.95%$6.02 (+2.21%)
Apr 20, 2026
7w ago
8-K
NEUTRAL ★ 3/10
$6.88 $6.20▼ −9.88%▼ −10.97%$6.02 (−12.50%)
Apr 14, 2026
8w ago
8-K
BULLISH ★ 7/10
$6.75 $6.99▲ +3.56%▲ +1.92%$6.02 (−10.81%)
Showing 3 of 3

US Market Status

Market Closed — Opens in 7h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access